Showing results (171-180 of 183) with videos related to

Sort By:
Pageof 19
Ecancermedicalscience|June 17, 2014
Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014)Michael Ewer, Luca Gianni, Fabrizio Pane, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2013
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapiesMatthew J Brauer, Guanglei Zhuang, Maike Schmidt, et al.
Clinical and Translational Science|September 25, 2021
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapySony Tuteja, Ramzi G Salloum, Amanda L Elchynski, et al.
Implementation Science Communications|May 15, 2022
Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapyRamzi G Salloum, Jeffrey R Bishop, Amanda L Elchynski, et al.
Journal of the National Cancer Institute|November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
Lancet (London, England)|February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Lijun Zhang, Michael Untch, et al.
Cancers|September 10, 2021
Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial ProfilerHelga Bergholtz, Jodi M Carter, Alessandra Cesano, et al.
Pageof 19